by George Fradley | Mar 28, 2023 | Case studies
A biotech had successfully completed Phase I clinical trials and was rapidly progressing into Phase II. Serious adverse event (SAE) volume was expected to significantly increase and therefore associated workload could not be managed in-house.Qinecsa established a...
by George Fradley | Mar 28, 2023 | Case studies
A small pharma client with limited budget had several clinical compounds in Phase I and II, and one globally approved commercial product. They required robust processes for the evaluation of single and aggregate data to strengthen stakeholder review and documentation...
by George Fradley | Mar 28, 2023 | Case studies
A small biotech with a healthy development pipeline had no internal pharmacovigilance expertise. They required a compliant drug safety framework to support safety data collection, evaluation, and dissemination during clinical trials. Qinecsa established a simple,...
by George Fradley | Dec 14, 2022 | Case studies
A specialty pharma company were experiencing complaints regarding their existing Medical Information Call Center (MICC) due to a high call abandon rate. Qinecsa provided Medical Information Call Center services in eight languages to support global 24/7/365 coverage,...
by George Fradley | Nov 22, 2022 | Case studies
A longstanding client approached Qinecsa with a business-critical mission to support case processing activities during the COVID pandemic. Qinecsa deployed a dedicated screening, recruitment, and onboarding team, including a project manager to manage all stakeholder...
by user | Sep 19, 2022 | Case studies
A global pharma company needed pharmacovigilance expertise following a European Medicines Agency inspection which resulted in several critical findings. They required a robust pharmacovigilance system that is compliant with the requirements of the FDA, EMA, and other...
